Ginkgo Bioworks Slips 2.57% as Investors Await Earnings
The stock fell while Zacks’ estimates pointed to lower quarterly revenue and a smaller loss compared with the year-earlier period.
Makkler Newsroom · Oct 2, 01:56 AM · 1 min read
Ginkgo Bioworks Holdings, Inc. Class A DNA
NYSEHealth ServicesUnited States
$9.61-0.62 (-6.06%)
Market closed· · USD · Data may be delayed
- Day's range
- 9.4010.05
- 52-week range
- 5.3718.22
Financial health
– / 5
Analyst view · 3 firms
Sell0 buy · 1 hold · 2 sell
Avg. target $8.00 (-16.8%)
Prices may be delayed and are for informational purposes only - not investment advice.